Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
2,112 questions in 171 reviews · Eyes and Vision
current versionsNo studies 587 · 27.8%Ungraded 95 · 4.5%Very low 446 · 21.1%Low 557 · 26.4%Moderate 361 · 17.1%High 66 · 3.1%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Any intervention vs steroid alone or plus levofloxacin Mean number of days from treatment initiation to resolution of symptoms or signs (shorter is favored) · epidemic keratoconjunctivitis Topical pharmacologic interventions versus placebo for epidemic keratoconjunctivitis (2022) · Cochrane | no estimate extracted | NR | Very low |
Vitrectomy vs vitreous tap biopsy and antibiotic injection Proportion of people with a visual acuity improvement of 10 letters or more · people with endophthalmitis following intraocular surgery Early vitrectomy for exogenous endophthalmitis following surgery (2022) · Cochrane | no estimate extracted | 1 study · 420 participants | Very low |
Vitrectomy vs vitreous tap biopsy and antibiotic injection Mean change in best‐corrected visual acuity · people with endophthalmitis following intraocular surgery Early vitrectomy for exogenous endophthalmitis following surgery (2022) · Cochrane | no estimate extracted | NR | No studies |
Vitrectomy vs vitreous tap biopsy and antibiotic injection Additional surgical procedure, including vitrectomy and cataract surgery. · people with endophthalmitis following intraocular surgery Early vitrectomy for exogenous endophthalmitis following surgery (2022) · Cochrane | RR 0.9 [0.66, 1.21] | 1 study · 420 participants | Low |
Vitrectomy vs vitreous tap biopsy and antibiotic injection Quality of life. · people with endophthalmitis following intraocular surgery Early vitrectomy for exogenous endophthalmitis following surgery (2022) · Cochrane | no estimate extracted | NR | No studies |
Vitrectomy vs vitreous tap biopsy and antibiotic injection Any adverse effects · people with endophthalmitis following intraocular surgery Early vitrectomy for exogenous endophthalmitis following surgery (2022) · Cochrane | no estimate extracted | 1 study · 420 participants | Very low |
Rho kinase inhibitor vs placeboa Glaucoma progression at 12 months, measured by additional visual field defects · people with primary open‐angle glaucoma or ocular hypertension Rho kinase inhibitor for primary open‐angle glaucoma and ocular hypertension (2022) · Cochrane | no estimate extracted | NR | No studies |
Rho kinase inhibitor vs beta‐blocker Glaucoma progression at 12 months, defined by anatomic (structural) criteriab · people with primary open‐angle glaucoma or ocular hypertension Rho kinase inhibitor for primary open‐angle glaucoma and ocular hypertension (2022) · Cochrane | no estimate extracted | NR | No studies |
Rho kinase inhibitor vs beta‐blocker Patient‐reported outcome at the longest · people with primary open‐angle glaucoma or ocular hypertension Rho kinase inhibitor for primary open‐angle glaucoma and ocular hypertension (2022) · Cochrane | no estimate extracted | NR | No studies |
Rho kinase inhibitor vs beta‐blocker Mean change in the number of glaucoma medications at the longest · people with primary open‐angle glaucoma or ocular hypertension Rho kinase inhibitor for primary open‐angle glaucoma and ocular hypertension (2022) · Cochrane | no estimate extracted | NR | No studies |
Rho kinase inhibitor vs beta‐blocker Need for additional treatment at the longest · people with primary open‐angle glaucoma or ocular hypertension Rho kinase inhibitor for primary open‐angle glaucoma and ocular hypertension (2022) · Cochrane | no estimate extracted | NR | No studies |
Rho kinase inhibitor vs beta‐blocker Number of ocular adverse events at the longest · people with primary open‐angle glaucoma or ocular hypertension Rho kinase inhibitor for primary open‐angle glaucoma and ocular hypertension (2022) · Cochrane | no estimate extracted | 4 studies · 1678 participants | Moderate |
Rho kinase inhibitor vs prostaglandin analog Glaucoma progression at 12 months, measured by additional visual field defects · people with primary open‐angle glaucoma or ocular hypertension Rho kinase inhibitor for primary open‐angle glaucoma and ocular hypertension (2022) · Cochrane | no estimate extracted | NR | No studies |
Rho kinase inhibitor vs prostaglandin analog Difference in mean IOP from baseline at < 6 months · people with primary open‐angle glaucoma or ocular hypertension Rho kinase inhibitor for primary open‐angle glaucoma and ocular hypertension (2022) · Cochrane | no estimate extracted | 4 studies · 1283 participants | Moderate |
Rho kinase inhibitor vs prostaglandin analog Glaucoma progression at 12 months, defined by anatomic (structural) criteriab · people with primary open‐angle glaucoma or ocular hypertension Rho kinase inhibitor for primary open‐angle glaucoma and ocular hypertension (2022) · Cochrane | no estimate extracted | NR | No studies |
Rho kinase inhibitor vs prostaglandin analog Patient‐reported outcome at the longest · people with primary open‐angle glaucoma or ocular hypertension Rho kinase inhibitor for primary open‐angle glaucoma and ocular hypertension (2022) · Cochrane | no estimate extracted | NR | No studies |
Rho kinase inhibitor vs prostaglandin analog Mean change in the number of glaucoma medications at the longest · people with primary open‐angle glaucoma or ocular hypertension Rho kinase inhibitor for primary open‐angle glaucoma and ocular hypertension (2022) · Cochrane | no estimate extracted | NR | No studies |
Rho kinase inhibitor vs placeboa Difference in mean IOP from baseline at < 6 months · people with primary open‐angle glaucoma or ocular hypertension Rho kinase inhibitor for primary open‐angle glaucoma and ocular hypertension (2022) · Cochrane | no estimate extracted | 3 studies · 155 participants | Low |
Rho kinase inhibitor vs prostaglandin analog Need for additional treatment at the longest · people with primary open‐angle glaucoma or ocular hypertension Rho kinase inhibitor for primary open‐angle glaucoma and ocular hypertension (2022) · Cochrane | no estimate extracted | NR | No studies |
Rho kinase inhibitor vs prostaglandin analog Number of ocular adverse events at the longest · people with primary open‐angle glaucoma or ocular hypertension Rho kinase inhibitor for primary open‐angle glaucoma and ocular hypertension (2022) · Cochrane | no estimate extracted | 4 studies · 1286 participants | Low |
Rho kinase inhibitor and prostaglandin analog vs prostaglandin analoga Glaucoma progression at 12 months, measured by additional visual field defects · people with primary open‐angle glaucoma or ocular hypertension Rho kinase inhibitor for primary open‐angle glaucoma and ocular hypertension (2022) · Cochrane | no estimate extracted | NR | No studies |
Rho kinase inhibitor and prostaglandin analog vs prostaglandin analoga Difference in mean IOP from baseline at < 6 months · people with primary open‐angle glaucoma or ocular hypertension Rho kinase inhibitor for primary open‐angle glaucoma and ocular hypertension (2022) · Cochrane | no estimate extracted | 3 studies · 1114 participants | Moderate |
Rho kinase inhibitor and prostaglandin analog vs prostaglandin analoga Glaucoma progression at 12 months, defined by anatomic (structural) criteriab · people with primary open‐angle glaucoma or ocular hypertension Rho kinase inhibitor for primary open‐angle glaucoma and ocular hypertension (2022) · Cochrane | no estimate extracted | NR | No studies |
Rho kinase inhibitor and prostaglandin analog vs prostaglandin analoga Patient‐reported outcome at the longest · people with primary open‐angle glaucoma or ocular hypertension Rho kinase inhibitor for primary open‐angle glaucoma and ocular hypertension (2022) · Cochrane | no estimate extracted | NR | No studies |
Rho kinase inhibitor and prostaglandin analog vs prostaglandin analoga Mean change in the number of glaucoma medications at the longest · people with primary open‐angle glaucoma or ocular hypertension Rho kinase inhibitor for primary open‐angle glaucoma and ocular hypertension (2022) · Cochrane | no estimate extracted | NR | No studies |
Rho kinase inhibitor and prostaglandin analog vs prostaglandin analoga Need for additional treatment at the longest · people with primary open‐angle glaucoma or ocular hypertension Rho kinase inhibitor for primary open‐angle glaucoma and ocular hypertension (2022) · Cochrane | no estimate extracted | NR | No studies |
Rho kinase inhibitor and prostaglandin analog vs prostaglandin analoga Number of ocular adverse events at the longest · people with primary open‐angle glaucoma or ocular hypertension Rho kinase inhibitor for primary open‐angle glaucoma and ocular hypertension (2022) · Cochrane | no estimate extracted | 4 studies · 1321 participants | Low |
Rho kinase inhibitor and prostaglandin analog vs rho kinase inhibitor Glaucoma progression at 12 months, measured by additional visual field defects · people with primary open‐angle glaucoma or ocular hypertension Rho kinase inhibitor for primary open‐angle glaucoma and ocular hypertension (2022) · Cochrane | no estimate extracted | NR | No studies |
Rho kinase inhibitor vs placeboa Glaucoma progression at 12 months, defined by anatomic (structural) criteriad · people with primary open‐angle glaucoma or ocular hypertension Rho kinase inhibitor for primary open‐angle glaucoma and ocular hypertension (2022) · Cochrane | no estimate extracted | NR | No studies |
Rho kinase inhibitor and prostaglandin analog vs rho kinase inhibitor Difference in mean IOP from baseline at < 6 months · people with primary open‐angle glaucoma or ocular hypertension Rho kinase inhibitor for primary open‐angle glaucoma and ocular hypertension (2022) · Cochrane | no estimate extracted | 3 studies · 1132 participants | Moderate |
Rho kinase inhibitor and prostaglandin analog vs rho kinase inhibitor Glaucoma progression at 12 months, defined by anatomic (structural) criteriab · people with primary open‐angle glaucoma or ocular hypertension Rho kinase inhibitor for primary open‐angle glaucoma and ocular hypertension (2022) · Cochrane | no estimate extracted | NR | No studies |
Rho kinase inhibitor and prostaglandin analog vs rho kinase inhibitor Patient‐reported outcome at the longest · people with primary open‐angle glaucoma or ocular hypertension Rho kinase inhibitor for primary open‐angle glaucoma and ocular hypertension (2022) · Cochrane | no estimate extracted | NR | No studies |
Rho kinase inhibitor and prostaglandin analog vs rho kinase inhibitor Mean change in the number of glaucoma medications at the longest · people with primary open‐angle glaucoma or ocular hypertension Rho kinase inhibitor for primary open‐angle glaucoma and ocular hypertension (2022) · Cochrane | no estimate extracted | NR | No studies |
Rho kinase inhibitor and prostaglandin analog vs rho kinase inhibitor Need for additional treatment at the longest · people with primary open‐angle glaucoma or ocular hypertension Rho kinase inhibitor for primary open‐angle glaucoma and ocular hypertension (2022) · Cochrane | no estimate extracted | NR | No studies |
Rho kinase inhibitor and prostaglandin analog vs rho kinase inhibitor Number of ocular adverse events at the longest · people with primary open‐angle glaucoma or ocular hypertension Rho kinase inhibitor for primary open‐angle glaucoma and ocular hypertension (2022) · Cochrane | no estimate extracted | 3 studies · 1131 participants | Low |
Rho kinase inhibitor and beta‐blocker vs beta‐blocker Glaucoma progression at 12 months, measured by additional visual field defects · people with primary open‐angle glaucoma or ocular hypertension Rho kinase inhibitor for primary open‐angle glaucoma and ocular hypertension (2022) · Cochrane | no estimate extracted | NR | No studies |
Rho kinase inhibitor and beta‐blocker vs beta‐blocker Difference in mean IOP from baseline at < 6 months · people with primary open‐angle glaucoma or ocular hypertension Rho kinase inhibitor for primary open‐angle glaucoma and ocular hypertension (2022) · Cochrane | no estimate extracted | 1 study · 208 participants | Moderate |
Rho kinase inhibitor and beta‐blocker vs beta‐blocker Glaucoma progression at 12 months, defined by anatomic (structural) criteriab · people with primary open‐angle glaucoma or ocular hypertension Rho kinase inhibitor for primary open‐angle glaucoma and ocular hypertension (2022) · Cochrane | no estimate extracted | NR | No studies |
Rho kinase inhibitor and beta‐blocker vs beta‐blocker Patient‐reported outcome at the longest · people with primary open‐angle glaucoma or ocular hypertension Rho kinase inhibitor for primary open‐angle glaucoma and ocular hypertension (2022) · Cochrane | no estimate extracted | NR | No studies |
Rho kinase inhibitor vs placeboa Patient‐reported outcome at the longest · people with primary open‐angle glaucoma or ocular hypertension Rho kinase inhibitor for primary open‐angle glaucoma and ocular hypertension (2022) · Cochrane | no estimate extracted | NR | No studies |
Rho kinase inhibitor and beta‐blocker vs beta‐blocker Mean change in the number of glaucoma medications at the longest · people with primary open‐angle glaucoma or ocular hypertension Rho kinase inhibitor for primary open‐angle glaucoma and ocular hypertension (2022) · Cochrane | no estimate extracted | NR | No studies |
Rho kinase inhibitor and beta‐blocker vs beta‐blocker Need for additional treatment at the longest · people with primary open‐angle glaucoma or ocular hypertension Rho kinase inhibitor for primary open‐angle glaucoma and ocular hypertension (2022) · Cochrane | no estimate extracted | NR | No studies |
Rho kinase inhibitor and beta‐blocker vs beta‐blocker Number of ocular adverse events at the longest · people with primary open‐angle glaucoma or ocular hypertension Rho kinase inhibitor for primary open‐angle glaucoma and ocular hypertension (2022) · Cochrane | no estimate extracted | 1 study · 208 participants | Moderate |
Rho kinase inhibitor vs placeboa Mean change in the number of glaucoma medications at the longest · people with primary open‐angle glaucoma or ocular hypertension Rho kinase inhibitor for primary open‐angle glaucoma and ocular hypertension (2022) · Cochrane | no estimate extracted | NR | No studies |
Rho kinase inhibitor vs placeboa Need for additional treatment at the longest · people with primary open‐angle glaucoma or ocular hypertension Rho kinase inhibitor for primary open‐angle glaucoma and ocular hypertension (2022) · Cochrane | no estimate extracted | NR | No studies |
Rho kinase inhibitor vs placeboa Average number of ocular adverse events at the longest · people with primary open‐angle glaucoma or ocular hypertension Rho kinase inhibitor for primary open‐angle glaucoma and ocular hypertension (2022) · Cochrane | no estimate extracted | 4 studies · 188 participants | Very low |
Rho kinase inhibitor vs beta‐blocker Glaucoma progression at 12 months, measured by additional visual field defects · people with primary open‐angle glaucoma or ocular hypertension Rho kinase inhibitor for primary open‐angle glaucoma and ocular hypertension (2022) · Cochrane | no estimate extracted | NR | No studies |
Rho kinase inhibitor vs beta‐blocker Difference in mean IOP from baseline at < 6 months · people with primary open‐angle glaucoma or ocular hypertension Rho kinase inhibitor for primary open‐angle glaucoma and ocular hypertension (2022) · Cochrane | no estimate extracted | 3 studies · 1415 participants | Low |
Intervention NR Proportion of participants with success, defined as 0 to trace cells or 2‐step decrease in activity SUN‐grading ( · Participants with a diagnosis of JIA and uveitis who are aged 2 to 18 years old Tumor necrosis factor (TNF) inhibitors for juvenile idiopathic arthritis‐associated uveitis (2022) · Cochrane | RR 0.66 [0.21, 2.1] | 2 studies · 43 participants | Low |
Intervention NR Risk of failure defined as 2‐step increase in activity in SUN grading ( · Participants with a diagnosis of JIA and uveitis who are aged 2 to 18 years old Tumor necrosis factor (TNF) inhibitors for juvenile idiopathic arthritis‐associated uveitis (2022) · Cochrane | RR 0.31 [0.01, 7.15] | 1 study · 31 participants | Low |